Literature DB >> 20658238

IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis.

Hiroto Yoshida1, Misato Hashizume, Masahiko Mihara.   

Abstract

We examined the time course of cytokine production by CD4 T cells from mice with collagen-induced arthritis (CIA), and we determined the influence of interleukin-6 (IL-6) blockade on cytokine production. CD4 T cells purified from spleen were cultured with both collagen and anti-CD28 antibody for 48 h and the production of interferon-γ (IFN-γ), IL-4, and IL-17 by the cells, secreted into the supernatants, was measured at various time intervals. The production of all these cytokines started 7 days after the first immunization. A marked increase in IFN-γ production was observed after the second immunization, but IL-4 and IL-17 production was not affected by a second immunization. A single injection of anti-mouse IL-6 receptor antibody (MR16-1) on the day of the first immunization suppressed the onset of arthritis. IL-17 production by CD4 T cells from MR16-1-treated mice was significantly lower than that from the control mice. On the other hand, treatment with MR16-1 showed only a tendency to suppress the production of IL-4 and IFN-γ. Injection of MR16-1 on day 21 did not suppress the onset of arthritis. We examined the direct influence of MR16-1 on cytokine production by differentiated CD4 T cells from arthritic mice. Production of IL-4, IFN-γ, and IL-17 was not affected by MR16-1. In conclusion, IL-6 inhibition preferentially suppresses the induction of Th17 cells and does not seem to impact on cytokine production of already differentiated Th17 cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658238     DOI: 10.1007/s00296-010-1552-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

1.  Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction.

Authors:  L A Joosten; E Lubberts; P Durez; M M Helsen; M J Jacobs; M Goldman; W B van den Berg
Journal:  Arthritis Rheum       Date:  1997-02

2.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

3.  Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis.

Authors:  A Doncarli; L M Stasiuk; C Fournier; O Abehsira-Amar
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

4.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

5.  Effect of a monoclonal antibody against interleukin-4 on collagen-induced arthritis in mice.

Authors:  S Yoshino
Journal:  Br J Pharmacol       Date:  1998-01       Impact factor: 8.739

6.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  N Takagi; M Mihara; Y Moriya; N Nishimoto; K Yoshizaki; T Kishimoto; Y Takeda; Y Ohsugi
Journal:  Arthritis Rheum       Date:  1998-12

7.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

Review 8.  Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.

Authors:  Masahiko Mihara; Yoshiyuki Ohsugi; Tadamitsu Kishimoto
Journal:  Biofactors       Date:  2009 Jan-Feb       Impact factor: 6.113

9.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

Review 10.  Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity.

Authors:  Edward F Rosloniec; Kary Latham; Yajaira B Guedez
Journal:  Arthritis Res       Date:  2002-07-17
View more
  7 in total

1.  Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model.

Authors:  Keisuke Tanaka; Misato Hashizume; Masahiko Mihara; Hiroto Yoshida; Miho Suzuki; Yoshihiro Matsumoto
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

2.  IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.

Authors:  N Narkbunnam; J Sun; G Hu; F-C Lin; T A Bateman; M Mihara; P E Monahan
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

3.  Role of interleukin-6 in hemopoietic and non-hemopoietic synergy mediating TLR4-triggered late murine ileus and endotoxic shock.

Authors:  B M Buchholz; R S Chanthaphavong; T R Billiar; A J Bauer
Journal:  Neurogastroenterol Motil       Date:  2012-04-10       Impact factor: 3.598

Review 4.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

Review 5.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.

Authors:  Masahiko Mihara; Yoshiyuki Ohsugi; Tadamitsu Kishimoto
Journal:  Open Access Rheumatol       Date:  2011-02-25

6.  Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis.

Authors:  Debbie M Roeleveld; Renoud J Marijnissen; Birgitte Walgreen; Monique M Helsen; Liduine van den Bersselaar; Fons A van de Loo; Peter L van Lent; Peter M van der Kraan; Wim B van den Berg; Marije I Koenders
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

7.  CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.

Authors:  Jilong Wu; Miaoni Zhou; Yinsheng Wan; Aie Xu
Journal:  Mol Med Rep       Date:  2012-10-08       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.